April 23, 2020 / 5:22 PM / a month ago

BRIEF-Gilead Says Regrets That WHO Prematurely Posted Data Regarding Remdesivir Study

April 23 (Reuters) - Gilead Sciences Inc:

* GILEAD SCIENCES SAYS “REGRET THAT THE WHO PREMATURELY POSTED” INFORMATION REGARDING ANTIVIRAL DRUG REMDESIVIR STUDY, WHICH HAS SINCE BEEN REMOVED

* GILEAD SAYS INVESTIGATORS IN REMDESIVIR STUDY DID NOT PROVIDE PERMISSION FOR PUBLICATION OF RESULTS

* GILEAD SAYS BECAUSE ANTIVIRAL DRUG REMDESIVIR STUDY WAS TERMINATED EARLY DUE TO LOW ENROLLMENT, IT WAS UNDERPOWERED TO ENABLE STATISTICALLY MEANINGFUL CONCLUSIONS

* GILEAD - STUDY RESULTS ARE INCONCLUSIVE; TRENDS IN DATA SUGGEST POTENTIAL BENEFIT FOR REMDESIVIR, PARTICULARLY AMONG PATIENTS TREATED EARLY IN DISEASE

* GILEAD - UNDERSTAND DATA HAS BEEN SUBMITTED FOR PEER-REVIEWED PUBLICATION, WHICH WILL PROVIDE MORE DETAILS FROM ANTIVIRAL DRUG STUDY IN NEAR FUTURE Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below